L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action
dc.contributor.author | Rose, Christopher | |
dc.contributor.author | Michalak, Adrianna | |
dc.contributor.author | Pannunzio, Pierre | |
dc.contributor.author | Therrien, Guy | |
dc.contributor.author | Quack, Guenter | |
dc.contributor.author | Kircheis, Gerald | |
dc.contributor.author | Butterworth, Roger | |
dc.date.accessioned | 2013-04-23T21:06:10Z | |
dc.date.available | 2013-04-23T21:06:10Z | |
dc.date.issued | 1998-06 | |
dc.identifier.uri | http://hdl.handle.net/1866/9581 | |
dc.subject | Ammonia | en |
dc.subject | Ammoniac | en |
dc.subject | Encéphalopathie hépatique | en |
dc.subject | Glutamine synthesis | en |
dc.subject | Hepatic Encephalopathy | en |
dc.subject | L-Aspartate de L-ornithine | en |
dc.subject | L-ornithine-L-aspartate | en |
dc.subject | Portal-systemic Encephalopathy | en |
dc.title | L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action | |
dc.type | Article | en |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine | fr |
dc.contributor.affiliation | Université de Montréal. Faculté de médecine. Centre de recherche du CHUM | fr |
dc.identifier.doi | 10.1023/A:1020613314572 | |
dcterms.abstract | Strategies aimed at the lowering of blood ammonia remain the treatment of choice in portal-systemic encephalopathy (PSE). L-ornithine-L-aspartate (OA) has recently been shown to be effective in the prevention of ammonia-precipitated coma in humans with PSE. These findings prompted the study of mechanisms of the protective effect of OA in portacaval-shunted rats in which reversible coma was precipitated by ammonium acetate administration (3.85 mmol/kg i.p.). OA infusions (300 mg/kg/h, i.v) offered complete protection in 12/12 animals compared to 0/12 saline-infused controls. This protective effect was accompanied by significant reductions of blood ammonia, concomitant increases of urea production and significant increases in blood and cerebrospinal fluid (CSF) glutamate and glutamine. Increased CSF concentrations of leucine and alanine also accompanied the protective effect of OA. These findings demonstrate the therapeutic efficacy of OA in the prevention of ammonia-precipitated coma in portacaval-shunted rats and suggest that this protective effect is both peripherally-mediated (increased urea and glutamine synthesis) and centrally-mediated (increased glutamine synthesis). | en |
dcterms.language | eng | en |
UdeM.VersionRioxx | Version acceptée / Accepted Manuscript | |
oaire.citationTitle | Metabolic brain disease | |
oaire.citationVolume | 13 | |
oaire.citationIssue | 2 | |
oaire.citationStartPage | 147 | |
oaire.citationEndPage | 157 |
Fichier·s constituant ce document
Ce document figure dans la ou les collections suivantes
Ce document diffusé sur Papyrus est la propriété exclusive des titulaires des droits d'auteur et est protégé par la Loi sur le droit d'auteur (L.R.C. (1985), ch. C-42). Il peut être utilisé dans le cadre d'une utilisation équitable et non commerciale, à des fins d'étude privée ou de recherche, de critique ou de compte-rendu comme le prévoit la Loi. Pour toute autre utilisation, une autorisation écrite des titulaires des droits d'auteur sera nécessaire.